RESUMO
Retention of 18F-Flortaucipir is reportedly increased in the semantic variant of primary progressive aphasia (svPPA), which is dominated by TDP-43 pathology. However, it is unclear if 18F-Flortaucipir is also increased in other TDP-43 diseases, such as bvFTD caused by a C9orf72 gene mutation. We therefore recruited six C9orf72 expansion carriers, six svPPA patients, and 54 healthy controls. All underwent 18F-Flortaucipir PET and MRI scanning. Data from 39 Alzheimer's Disease patients were used for comparison. PET tracer retention was assessed both at the region-of-interest (ROI) and at the voxel-level. Further, autoradiography using 3H-Flortaucipir was performed. SvPPA patients exhibited higher 18F-Flortaucipir retention in the lateral temporal cortex bilaterally according to ROI- and voxel-based analyses. In C9orf72 patients, 18F-Flortaucipir binding was slightly increased in the inferior frontal lobes in the ROI based analysis, but these results were not replicated in the voxel-based analysis. Autoradiography did not show specific binding in svPPA cases or in C9orf72-mutation carriers. In conclusion, temporal lobe 18F-Flortaucipir retention was observed in some cases of svPPA, but the uptake was of a lower magnitude compared to AD dementia. C9orf72-mutation carriers exhibited none or limited 18F-Flortaucipir retention, indicating that 18F-Flortaucipir binding in TDP-43 proteinopathies is not a general TDP-43 related phenomenon.
Assuntos
Carbolinas/farmacocinética , Proteínas de Ligação a DNA/metabolismo , Proteinopatias TDP-43/metabolismo , Lobo Temporal/metabolismo , Proteínas tau/metabolismo , Idoso , Idoso de 80 Anos ou mais , Proteína C9orf72/genética , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Mutação , Tomografia por Emissão de Pósitrons , Ligação Proteica , Proteinopatias TDP-43/patologia , Lobo Temporal/patologiaRESUMO
A case with giant cell arteritis causing infarction of two segments of the small bowel is described in a 43-year-old woman. Subsequent angiography showed stenoses in both subclavian arteries and one common iliac artery, compatible with Takayasu's disease. The difficulties in distinguishing the different types of granulomatous giant cell arteries are discussed.
Assuntos
Arterite de Células Gigantes/complicações , Infarto/etiologia , Intestino Delgado/irrigação sanguínea , Adulto , Feminino , Humanos , Artéria Ilíaca/diagnóstico por imagem , Infarto/cirurgia , Intestino Delgado/cirurgia , Radiografia , Artéria Subclávia/diagnóstico por imagemRESUMO
The case histories of two patients with cavitary pulmonary nodules and the findings at chest radiography are reviewed. The first patient had a connective tissue disease with features common to systematic lupus erythematosus and Wegener's granulomatosis. In the second patient the lung changes developed as part of a drug reaction to carbamezapine and/or phenytoin. The common denominator of the cavitating nodules is probably the presence of granulomas, developing as a sequela of pulmonary vasculitis.
Assuntos
Doenças do Colágeno/complicações , Hipersensibilidade a Drogas/complicações , Pneumopatias/diagnóstico por imagem , Adulto , Anticonvulsivantes/efeitos adversos , Doenças do Colágeno/diagnóstico por imagem , Feminino , Humanos , Pulmão/diagnóstico por imagem , Pneumopatias/induzido quimicamente , Pneumopatias/etiologia , Lúpus Eritematoso Sistêmico/induzido quimicamente , Lúpus Eritematoso Sistêmico/complicações , Pessoa de Meia-Idade , RadiografiaRESUMO
Nine out of 39 uremic patients treated with sulphonamides because of urinary tract infection developed hemolysis. Heinz-bodies were seen in all cases. In uremic patients a defect of the HMP metabolic pathway renders these patients susceptible to hemolysis when treated with oxidant drugs.
Assuntos
Síndrome Hemolítico-Urêmica/induzido quimicamente , Sulfonamidas/efeitos adversos , Uremia/complicações , Infecções Urinárias/tratamento farmacológico , Corpos de Heinz/análise , Humanos , Uremia/metabolismoRESUMO
An investigation has been performed with a new parenteral iron preparation, iron-poly-(sorbitol-gluconic acid) complex (Ferastral) in the treatment with iron deficiency anaemia associated with inflammatory diseases, mainly rheumatoid arthritis. Fifteen moderately anaemic patients entered into the trial. These patients constituted a special group in whom the MCHCs were subnormal. Observations were made concerning the occurrence of side-effects. Particular attention was paid to those-side-effects which are known to be associated with the use of parenteral iron preparations in the treatment of rheumatoid subjects. Ferastral was administered by intramuscular by intramuscular injection. The single doses given on any one occasion varied from a minimum of 100 mg to a maximum of 500 mg, divided into two separate injections. The results of therapy, measured at eight weeks, showed significant increases in haemoglobin concentrations. Increases in erythrocyte count, MCHC and serum-iron concentration were also found. There were no signs of acute toxic effects with Ferastral and in no patient was there exacerbation of arthritis as has been previously reported with iron-dextran.
